Combo Regimen May Improve Pathologic Complete Response Rate in TNBC in Early Ph 2 INVINCIBLE-4 of INT230-6 March 17, 2026
Positive Ph 3 Interim Topline Results for izalontamab brengitecan (Iza-bren) in Unresectable Locally Advanced or Metastatic 1L TNBC Highlighted March 3, 2026
DATROWAY Supplemental NDA Submitted in Japan for Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy February 25, 2026
DATROWAY® Granted Priority Review in the US in 1L Metastatic TNBC Patients Who Are Not Candidates for Immunotherapy February 9, 2026
Trodelvy® Added as Preferred Regimen Within 1L Metastatic TNBC in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) February 1, 2026
NEJM Publishes Ph 3 ASCENT-04/KEYNOTE-D19 Results of Trodelvy + Keytruda in 1L PD-L1+ Metastatic TNBC January 25, 2026
DATROWAY® Type II Variation Application Validated in the EU for Patients with 1L Metastatic, IO-ineligible TNBC December 22, 2025
Pan Cancer T Secures EUR 10M to Advance First-in-Human Trial of PCT1:CO-STIM in TNBC December 15, 2025
Updated Efficacy Data of Ivonescimab Combined with Chemo as 1L Treatment for TNBC Presented December 15, 2025
Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for TNBC December 9, 2025
No median OS difference observed in TNBC patients treated with nadunolimab + gemcitabine/carboplatin (GC) vs GC in Ph 1b/2 TRIFOUR study December 9, 2025
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement with QIMR Berghofer for a first-in-class PD-L1 degrader program October 16, 2025
Datroway demonstrated statistically significant OS & PFS improvement in 1L metastatic IO-ineligible TNBC patients in TROPION-Breast02 trial October 8, 2025
86% Reduction in Tumor Burden Announced in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen October 7, 2025
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in TNBC September 30, 2025
First Patient Dosed in Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs August 19, 2025
Regulatory Clearance obtained to Initiate Ph 1 Trial for PQ203 in the U.S. and Canada; FDA Fast Track Designation Granted August 11, 2025
Preliminary topline efficacy results from Ph 2 TRIFOUR trial of nadunolimab in advanced TNBC announced July 23, 2025
